Date: 2017-02-13
Type of information: Development agreement
Compound: long duration, controlled release formulations of a peptide therapeutic
Company: Ferring Pharmaceuticals (Switzerland) Foresee Pharmaceuticals (Taiwan)
Therapeutic area:
Type agreement: development
Action mechanism:
Disease:
Details: * On February 13, 2017, Ferring Pharmaceuticals and Foresee Pharmaceuticals have entered into an exclusive worldwide development and option agreement to leverage Foresee’s proprietary and unique stabilized injectable formulation platform (SIF) for the development of long duration, controlled release formulations of a peptide therapeutic.
Financial terms: Under the terms of the agreement, Ferring will fund the development work and, upon completion, Ferring will have the right to exercise its option and enter into a definitive agreement with Foresee. Execution of a definitive agreement would entitle Foresee to additional payments including upfront, milestones and royalties based on net sales of the product(s) commercialized by Ferring.
Latest news:
